Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 17, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the ...
MADRID — Individuals with type 2 diabetes and/or obesity plus one or more metabolic risk factors are at a higher risk for metabolic dysfunction–associated steatotic liver disease (MASLD) with fibrosis ...
MADRID — Once-weekly insulin, new incretin drugs, diabetes complications, and joint society collaborations will be among the featured topics at the European Association for the Study of Diabetes (EASD ...
Dissemination of a French Regulatory News, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. in prediabetes and type 2 diabetes at the 2024 European ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results